An underappreciated aspect of neurotrophin receptors is the proteolytic cleavage of the p75 neurotrophin receptor, which gives rise to a soluble extracellular domain (ECD). This event occurs frequently, resulting in large amounts of shedding of the p75 ECD, which was easily detected in urine, plasma and amniotic fluid.
1 Moreover, the shedding of the ECD is developmentally regulated and increases after nerve lesion. The biological consequences of the production of the ECD half of p75 have remained a mystery for decades.
The appearance of the p75 ECD was originally detected in Schwann cells after axotomy, 1 but has been also found in the brain after injury or pathological conditions. 2 The recent study by Yao et al. 2 indicates that one function of the p75 ECD is to protect against amyloid-beta peptide toxicity. This is a very intriguing observation, given that p75 receptor signaling has been associated with neurodegeneration and cell death through the binding to pro-neurotrophins. 3 Why do neurotrophins induce a cell death signal, as well as produce trophic support to many neuronal populations?
The p75 neurotrophin receptor is the founding member of the large tumor necrosis factor receptor superfamily, and participates in many critical processes in the nervous system, ranging from apoptosis to synaptic plasticity and morphological events. It was initially identified as a nerve growth factor receptor, but has many other ligands (BDNF, NT-3, NT-4; pro-neurotrophins), as well as co-receptors, such as Nogo, Lingo-1, sortilin/SorCS2 (sortilin-related VPS10 domain-containing receptor 2), and numerous cytoplasmic adaptor proteins and enzymatic activities. 4, 5 It has been recognized for some time that p75 can cooperate with Trk receptors to enhance neuronal survival and differentiation, whereas sortilin or SorCS2 proteins participate with p75 in cell death and growth cone retraction. 6 Alternatively, p75 and the Nogo receptor can mediate axonal growth-inhibitory effects of myelin. 7 Hence, p75 stands at a focal point to explain a wide range of cellular functions including apoptosis during development and following injury, remodeling of neuronal morphology and changes in synaptic plasticity. 3 In a recent study published in Molecular Psychiatry, Yao et al. showed that the p75 ectodomain accumulated normally in mouse brain after 6 months of age. On the other hand, levels of the p75 ECD protein were decreased in the cortex of APPswe/PS1 transgenic mice, as well as in CSF samples from postmortem AD patients. Transduction of AAV-ECD-Fc in the lateral ventricle of APPswe/PS1 mice restored the levels of p75 ECD and resulted in a reduction of amyloid plaque burden in the cortical and hippocampal regions of APPswe/PS1 mice.
Administration of p75ECD-Fc in APPswe/PS1 mice resulted in a reduction of Aβ levels in the brain and serum after 12 months of age. One explanation is the prevention of fiber formation by p75ECD-Fc, which also results in a disaggregation of Aβ fibrils, as assayed by thioflavin T fluorescence, and in blocking Aβ-dependent amyloidogenic processing. 2, 8 The p75 ECD also blocks Aβ-induced BACE (beta-secretase) levels. Several other effects of the p75 ECD were observed that involve an increase in the levels of synaptic proteins, such as SNAP 25, PSD-95 and synapsin, together with decreases in serine and threonine phosphorylation sites on tau. Remarkably, markers of activated astrocytes and microglia were reduced in the cortex and hippocampus. By several behavioral criteria, APPswe/PS1 mice treated with the AAV-ECD-Fc performed better in open field, Morris water maze, and Y maze assays than AAV-GFP-treated mice.
What accounts for the ability of the p75 ECD to produce so many effects in the AD mouse model? One way to think about the role of neurotrophin receptor signaling is that p75 binds to multiple ligands and oligomeric states, which can give rise to different outcomes. In addition to nerve growth factor family members and pro-neurotrophins, Aβ peptides have often been proposed as ligands for p75. Previous competition binding studies demonstrated an interaction between Aβ40 peptide and p75, and not to the TrkA receptor. 9 The p75 receptor is a type I transmembrane receptor that has four cysteine-rich domains of 40 amino acids, each containing three intrachain disulfide bridges and numerous glycosylation sites. One distinctive feature of the p75 ECD domain is its highly negative charged properties; it displays a net charge of − 24. Hence the ECD is potentially capable of binding or sequestering many substrates and proteins, which may affect amyloid processing.
The shedding of the ectodomain of the p75 receptor gives rise to several important effects in the brain. Another overlooked cleavage event of p75 is through gamma-secretase activity (Figure 1) . Although the intracellular domain of p75 (ICD) does not have intrinsic enzymatic activity, signaling is thought to occur through interaction of the ICD with cytoplasmic adaptor proteins. Like the amyloid precursor protein, p75 undergoes an α-secretase cleavage above the transmembrane domain, 10 which involves the TACE metalloproteinase, and an intramembraneous cleavage by γ-secretase. Curiously, the cleavage of p75 by γ-secretase is at a very similar site and sequence as the cleavage of the transmembrane domain of APP. The extent of cleavage is believed to be regulated, but it is unclear how the cleavage of APP and p75 is controlled. Recent evidence suggests that different neuronal populations that express p75 result in a different pattern of γ-secretase cleavage, 11 which can change the signaling of p75. It is apparent there is a close juxtaposition of neurotrophin signaling with APP metabolism. Previous studies indicated that the loss of trophic support leads to dramatic effects upon amyloidogenic processing through signaling by p75 and Trk receptors and their interacting partners. 12 The evidence that p75 ECD is downregulated in Alzheimer's brain provides a useful diagnostic biomarker. The p75 ECD protein is easily detected in plasma and CSF. Understanding the early receptor processing and signaling events following trophic factor withdrawal from target neurons will lead to insights not only into amyloidogenic mechanisms, but also into many neuropsychiatric conditions where p75 is considerably upregulated after injury, inflammation and aging. Figure 1 . The p75 neurotrophin receptor possesses four canonical cysteine-rich domains (blue), a single-membrane spanning domain and a cytoplasmic death domain (red). Cleavage above the membrane by a specific α-secretase, such as TACE, releases the ectodomain domain (ECD). Subsequent cleavage in the transmembrane domain by the γ-secretase complex gives rise to the intracellular cytoplasmic domain (ICD). 10, 11 
